




CRISPR Cpf1 antibodies now available


The bacterial CRISPR-Cas9 system marked a major technological advance over zinc-finger nucleases and TALENs as a tool for genomic engineering. However, ongoing research has generated modifications and revealed new systems that offer considerable improvements over the standard CRISPR-Cas9 methodology (reviewed by Nakade, S., *et al.*¹). These include engineered Cas9 variants, Cas9 homologs, and Cpf1, a class 2/type V CRISPR effector. The Cpf1 proteins from the bacteria *Acidaminococcus* and *Lachnospiraceae* were found to efficiently perform gene editing in human cells². And while Cas9 and Cpf1 share some properties, Cpf1 offers several distinct advantages:

1. [Cpf1 is a single crRNA-guided endonuclease, and does not require a tracrRNA to mediate interference.](#)
2. [Cpf1 generates sticky ends, instead of the blunt ends produced by Cas9.](#)
3. [Cpf1 utilizes a T-rich PAM sequence.](#)
4. [Cpf1 also possesses an RNase III function for pre-crRNA processing.](#)


GeneTex proudly offers six excellent Cpf1 antibodies against different regions of the Cpf1 proteins from either *Acidaminococcus* or *Lachnospiraceae*. See the products below or [click here](#) to find more information.




[Cpf1 antibody \(GTX133296\)](#)



[Cpf1 antibody \(GTX133298\)](#)



[Cpf1 antibody \(GTX133299\)](#)



[Cpf1 antibody \(GTX133300\)](#)

References:

1. [Bioengineered. 2017 Jan 31:0.](#)
2. [Cell. 2015 Oct 22;163\(3\):759-71.](#)